Bristol Myers' Krazati Demonstrates Encouraging Activity in Colorectal Cancer Treatment

Monday, 8 April 2024, 16:00
The Phase 1/2 study conducted by Bristol Myers on their oncology drug Krazati has unveiled significant positive outcomes in treating KRAS G12C-mutated colorectal cancer. The study shows promising and clinically relevant results, signaling potential advancements in the field of cancer treatment, specifically for this subtype of colorectal cancer.
https://store.livarava.com/abdc8933-f5c1-11ee-897e-87cc5c87fb08.jpg
Bristol Myers' Krazati Demonstrates Encouraging Activity in Colorectal Cancer Treatment

Bristol Myers Reveals Positive Data for Krazati in Colorectal Cancer

Bristol Myers (BMY) announced the findings of its Phase 1/2 study on Krazati, emphasizing its effectiveness in treating KRAS G12C-mutated colorectal cancer. The study highlighted the significant activity and potential breakthrough in cancer therapy.

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe